Two Dimensions in Targeting HER2

[11] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1124 - 1130

[12] A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies [J]. CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6702 - 6708

[13] A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer [J]. ANNALS OF ONCOLOGY, 2008, 19 (06) : 1068 - 1074

[14] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307

[15] Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes [J]. ONCOGENE, 2008, 27 (27) : 3870 - 3874

[16] Stimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer [J]. JOURNAL OF IMMUNOLOGY, 2011, 187 (02) : 1031 - 1038

[17] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J]. NATURE, 2003, 421 (6924) : 756 - 760

[18] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446

[19] CORTES J, 2009, J CLIN ONCOL S, V27, pS46

[20] Cuello M, 2001, CANCER RES, V61, P4892

[11] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1124 - 1130

[12] A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies [J]. CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6702 - 6708

[13] A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer [J]. ANNALS OF ONCOLOGY, 2008, 19 (06) : 1068 - 1074

[14] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307

[15] Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes [J]. ONCOGENE, 2008, 27 (27) : 3870 - 3874

[16] Stimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer [J]. JOURNAL OF IMMUNOLOGY, 2011, 187 (02) : 1031 - 1038

[17] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J]. NATURE, 2003, 421 (6924) : 756 - 760

[18] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446

[19] CORTES J, 2009, J CLIN ONCOL S, V27, pS46

[20] Cuello M, 2001, CANCER RES, V61, P4892